Bioanalytical assessment of Cetuximab in Wistar rat plasma using nSMOL and LCMS-8060

Introduction

Cetuximab is a human monoclonal antibody (mAb) for the treatment of metastatic colorectal carcinoma, head and neck cancer. Cetuximab was first approved by U.S. FDA in 2004. Generally bioanalysis of mAB drugs is based on Ligand Binding Assay (LBA). However LBA tends to show larger variability and development time for assay can be longer. Hence in this work, we present bioanalysis of Cetuximab in Wistar rat plasma using nSMOL^TM (nano surface molecular orientation limited proteolysis) reagent kit and LCMS-8060, triple quadrupole from Shimadzu Corporation.

January 7, 2020 GMT